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Online supplement 
Obstructive Sleep Apnea and Diabetic 
retinopathy in Patients with Type 2 
Diabetes: A Longitudinal Study 
OSA severity and DR 
In order to assess the relationship between OSA severity and STDR, we used the logistic regression 
model shown in Table 4. Inserting OSA as a three category variable (no OSA, mild and moderate to 
severe OSA) demonstrated that mild (OR 2.7, 95%CI 1.2-6.1, p=0.01) but not moderate to severe (OR 
1.9, 95%CI 0.7-4.8, p=0.1) OSA was independently associated with STDR. A similar association was 
found with maculopathy (mild OSA- OR 3.1, 95%CI 1.3-7.1, p=0.006; and moderate to severe OSA- 
OR 2.3, 95%CI 0.9-6.1, p=0.08) and advanced DR (mild OSA- OR 3.0, 95%CI 0.9-9.9, p=0.06; and 
moderate to severe OSA- OR 3.1, 95%CI 0.8-12.3, p=0.09).  
To assess the relationship between OSA and ODI and STDR as well as maculopathy and advanced DR 
we used AHI and ODI tertiles instead of OSA in the same model detailed in Table 4. The AHI tertiles 
were: tertile 1 AHI < 4.8 events/hour, tertile 2 AHI 4.8-11.89 events/hour and tertile 3 ≥ 11.90 
events/hour. The ODI tertiles were tertile 1 ODI < 4.1 events/hour, tertile 2 ODI 4.1-11.39 
events/hour and tertile 3 ODI ≥ 11.40 events/hour. 
After adjusting for ethnicity, age at diabetes diagnosis, diabetes duration, gender, HbA1c, BMI, 
systolic blood pressure, insulin use, number of anti-hypertensive agents, oral anti-hyperglycaemic 
agents and eGFR there was a non-significant trend of association between AHI tertiles and STDR 
(Nagelkerke R2 for the model= 0.32); the OR (95%CI) for AHI tertiles 2 and 3 considering tertile 1 as 
the reference point were  OR 1.9 (95% CI 0.8-4.4, p=0.1) and OR 2.1 (95%CI 0.9-5.0, p=0.1) 
respectively. Replacing AHI tertiles with ODI tertiles showed that the association with tertile 2 was 
statistically significant. After similar adjustments (Nagelkerke R2 for the model= 0.33); the OR 
(95%CI) for ODI tertiles 2 and 3 considering tertile 1 as the reference point were OR 2.6 (95%CI 1.2-
5.9, p=0.02) and OR 1.8 (95%CI 0.7-4.3, p=0.2) respectively.  
Repeating the same analysis but replacing the outcome measure from STDR to maculopathy showed 
that tertiles 2 of the AHI and ODI were significantly associated with maculopathy at baseline with a 
non-significant trend of association with tertiles 3 of the AHI and ODI. The OR (95%CI) for tertiles 2 
and 3 of AHI were (Nagelkerke R2 for the model 0.27) OR 2.5 (95%CI 1.1-5.7, p=0.03) and OR 2.2 
(95%CI 0.9-5.4, p=0.09) respectively. The OR (95%CI) for tertiles 2 and 3 of ODI were (Nagelkerke R2 
for the model 0.27) OR 2.5 (95%CI 1.1-5.6, p=0.03) and OR 1.8 (95%CI 0.7-4.4, p=0.2) respectively. 
Repeating the analysis but changing the outcome measure to advance DR showed a non-significant 
association between advanced DR and tertiles 2 and 3 of AHI and ODI. For AHI tertiles 2 and 3 
(Nagelkerke R2 for the model 0.31) the OR (95%CI) were OR 2.7 (95%CI 0.8-9.0, p=0.1) and OR 2.8 
(95%CI 0.8-10.3, p=0.1) respectively. For ODI tertiles 2 and 3 (Nagelkerke R2 for the model 0.32) the 
OR (95%CI) were OR 3.2 (95%CI 1.0-10.4, p=0.05) and OR 2.5 (95%CI 0.7-8.9, p=0.2) respectively. 
Characteristics of the study population that was examined for the 
progression to advanced DR 
164 patients included in this analysis of which 66 (40.2%), 60 (36.6%), 19 (11.6%) and 19 (11.6%) had 
no, mild, moderate and severe OSA respectively. All patients with moderate to severe OSA (n=38) 
were referred to the sleep clinic in the NHS trust and that’s why we had 38 patients in the CPAP 
table in the online supplement. The baseline characteristics of the 164 patients who were included 
in the progression to advanced DR analysis are summarised in Table 1 of the online supplement. The 
characteristics of this population are in line with the characteristics of the total population at 
baseline (Table 2 of the main manuscript) 
 
 Table 1 of the online supplement: The baseline characteristics of the 164 patients who were 
included in the progression to advanced DR analysis. Data presented as mean (SD) or % (n). Analysis 
performed using the Chi-square test for categorical variables, the independent t test for normally 
distributed variables and the Mann-Whitney U test for non-normally distributed variables. 
 OSA- (n=66) OSA+ (n=98) P value 
Male 40.9% (27) 66.3% (65) 0.001 
White European 31.8% (21) 56.1% (55) 0.002 
Age (years) 54.9 (11.3) 
 
58.8 (11.9) 0.02 
Diabetes duration (years) 10.9 (7.3) 
 
12.1 (7.2) 0.18 
Body Mass Index (kg/m2) 31.6 (7.3) 
 
36.0 (10.0) 0.001 
Waist circumference (cm) 105.7 (13.7) 
 
115.6 (16.9) < 0.001 
Systolic blood pressure (mmHg) 124.1 (15.6) 
 
132.2 (13.9) 0.001 
Diastolic blood pressure (mmHg) 76.9 (10.5) 
 
78.3 (9.6) 0.63 
HbA1c (%) 7.8 (1.3) 
 
8.2 (1.3) 0.02 
Total cholesterol (mmol/L) 4.0 (1.1) 3.8 (0.9) 0.20 
Triglycerides (mmol/L) 1.9 (1.3) 
 
2.0 (1.2) 0.30 
Estimated GFR (ml/min/1.73 m2) 93.1 (23.2) 
 
85.4 (26.5) 0.03 
Epworth sleepiness score  6.2 (5.9) 
 
8.9 (5.8) 0.003 
Smoking (current or ex-smoker) 37.9% (25) 38.8% (38) 0.91 
Alcohol (consumes alcohol) 10.6% (7) 23.5% (23) 0.04 
Oral hypoglycaemic agents 98.5% (65) 88.8% (87) 0.03 
Thiazolidinediones 15.2% (10) 12.2% (12) 0.59 
Insulin 37.9% (25) 55.1% (54) 0.03 
GLP-1 analogue 4.5% (3) 11.2% (11) 0.13 
Anti-hypertensive agents 72.7% (48) 83.7% (82) 0.09 
Lipid lowering therapy 89.4% (59) 84.7% (83) 0.39 
Fibrates 6.1% (4) 4.4% (4) 0.72 
Anti-platelet agents 62.1% (41) 71.4% (70) 0.21 
Ischemic heart disease 15.2% (10) 23.5% (23) 0.19 
Diabetic nephropathy  20.3% (13) 47.9% (45) < 0.001 
 
 
 
The impact of HbA1c changes during the follow-up on the relationship 
between OSA and progression to advanced DR 
 
As hyperglycaemia is a major risk factor for the development of DR, we wanted to explore whether 
changes in HbA1c from baseline are responsible for the associations observed between OSA and 
progression to advanced DR. The follow up HbA1c was collected mostly in 2013 and 2014 using the 
latest HbA1c available in the electronic patients records. The median (IQR) follow up duration for 
HbA1c in patients in whom we made the assessment for progression to advanced DR was 3.8 (3.3-
4.4) years vs. 4.0 (3.4-4.5) years for patients without vs. with OSA (p=0.2). The longitudinal changes 
in HbA1c based on OSA status at baseline in patients in which we made the advanced DR 
progression assessment are summarised in Table 2 of the online supplement.  HbA1c change was 
calculated as study-end HbA1c – baseline HbA1c (i.e. positive numbers indicate worsening HbA1c).  
Table 2 of the online supplement: Changes in HbA1c and their relationship to OSA status during the 
study follow-up. Data presented as mean (SD) or median (IQR). *indicate p value for the difference 
between patients with and without OSA; $indicate p value for the difference between baseline and 
study end in the same OSA status category. The sample size analysis is 164 at baseline and 163 
patients at study-end as there is one HbA1c measurement missing from a patient with OSA at 
baseline. 
 Baseline HbA1c Study-end HbA1c P value$ HbA1c change 
No OSA (n=66) 7.8 (1.3) % 8.1 (1.6) % 0.03 0.1 (-0.3 to 0.8) 
OSA (n=97) 8.2 (1.3) % 8.1 (1.8) % 0.6 0.0 (-0.8 to 0.7) 
P value* 0.02 0.9  0.07 
 
The results show that in the no OSA group HbA1c has worsened over the follow up period while it 
remained stable in patients with OSA. However, despite the worsening of HbA1c in patients without 
OSA, OSA was associated with the progression to advanced DR. 
Adding change in HbA1c in the logistic regression model showed that OSA remained associated with 
the development of progression to advanced DR (Nagelkerke R2 0.42; OR 5.3; 95%CI 1.2-23.5, 
p=0.03). Similarly, adjusting for study-end HbA1c instead of HbA1c change did not affect the results 
and OSA remained associated with progression to advanced DR (Nagelkerke R2 0.42; OR 5.3, 95%CI 
1.2-23.5, p=0.03). 
Hence, in summary, HbA1c change during the follow up did not explain the observed relationship 
between OSA and progression to advanced DR. 
CPAP and DR progression 
Out of 164 patients that were included in the progression to advanced DR analysis, 38 had moderate 
to severe OSA and only 15 were CPAP-compliant.  Summary of patient characteristics according to 
CPAP compliance can be found in Table3 of the online supplement. There were largely no 
differences between patients who were and were not compliant with CPAP; apart from that the AHI 
was higher in the CPAP compliant group and use of diabetes treatment (both oral anti-diabetic drugs 
and insulin) was higher in CPAP non-compliant group. 
Progression to advanced DR occurred in 6% (n=4) vs. 15.3% (n=9) vs.39.1% (n=9) vs. 0% (n=0) in 
patients with no OSA, mild OSA, moderate to severe OSA non-compliant with CPAP and moderate to 
severe OSA compliant with CPAP respectively (p<0.001). 
Out of 129 patients included in the progression to maculopathy analysis, 28 patients had moderate 
to severe OSA, of which 11 were CPAP-compliant. Progression to maculopathy occurred in 19.0% 
(n=11), 18.6% (n=8), 35.3% (n=6) and 9.1% (n=1) in patients with no OSA, mild OSA, moderate to 
severe OSA non-compliant with CPAP and moderate to severe OSA compliant with CPAP respectively 
(p=0.34). Similar trends were found in the progression to sight threatening DR analysis but results 
were not statistically significant. 
Table 3 of the online supplement: Comparison of the characteristics of patients who were and 
were not compliant with CPAP treatment.  Data presented as mean (SD) or n (%) of the respective 
CPAP group. 
 CPAP non -compliant 
(n=23) 
CPAP compliant 
(n=15) 
P value 
Male  19 (82.6%) 9 (60.0%) 0.002 
White Europeans  15 (65.2%) 11 (73.3%) 0.003 
Age (years)  61.3 (9.5) 61.9 (7.0) 0.82 
Diabetes Duration (years)  13.0 (6.7) 12.0 (8.0) 0.94 
Body Mass Index (kg/m2)  36.3 (9.0) 39.4 (10.1) 0.34 
Waist circumference (cm)  118.3 (14.9) 119.4 (19.3) 0.85 
Systolic blood pressure (mmHg) 131.4 (15.2) 135.6 (14.4) 0.40 
HbA1c (%)  8.0 (1.5)  7.7 (1.0) 0.42 
Total cholesterol (mmol/L)  3.6 (0.7) 4.0 (1.2)  0.20 
Triglycerides (mmol/L)  2.2 (0.9) 1.5 (0.8) 0.01 
AHI (events/hour)  31.1 (18.7) 43.7 (25.1) 0.08 
Epworth sleepiness score  9.9 (6.0) 10.6 (4.7) 0.7 
Oral anti-diabetes treatment 22 (95.7%) 12 (80.0%) 0.03 
Insulin  13 (56.5%) 6 (40.0%) 0.07 
Anti-hypertensive agents  20 (87.0%) 14 (93.3%) 0.2 
Lipid lowering treatment  20 (87.0%) 15 (100.0%) 0.1 
Anti-platelets  18 (78.3%) 11 (73.3%) 0.5 
 
 
 
 
Figure 1 of the online supplement: The follow up duration in patients with no DR at baseline (R0) 
according to study-end DR grade in patients with and without OSA. DR: diabetic retinopathy. There 
was no progression from R0 to R2. 
 
